{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:49:40Z","timestamp":1792763380690,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1038\/s41431-022-01055-4","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T05:02:36Z","timestamp":1644210156000},"page":"1155-1158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The case for screening in early life for \u2018non-treatable\u2019 disorders: ethics, evidence and proportionality. A report from the Health Council of the Netherlands"],"prefix":"10.1038","volume":"30","author":[{"given":"Shona","family":"Kalkman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4052-7192","authenticated-orcid":false,"given":"Wybo","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"1055_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/ejhg.2016.126","volume":"25","author":"ME Jansen","year":"2016","unstructured":"Jansen ME, Metternick-Jones SC, Lister KJ. International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents. Eur J Hum Genet. 2016;25:10\u20136.","journal-title":"Eur J Hum Genet"},{"key":"1055_CR2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/ajmg.a.31165","volume":"140","author":"LF Ross","year":"2006","unstructured":"Ross LF. Screening for conditions that do not meet the Wilson and Jungner criteria: the case of Duchenne muscular dystrophy. Am J Med Genet A. 2006;140:914\u201322.","journal-title":"Am J Med Genet A."},{"key":"1055_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/mrdd.20119","volume":"12","author":"DB Bailey Jr.","year":"2006","unstructured":"Bailey DB Jr., Beskow LM, Davis AM, Skinner D. Changing perspectives on the benefits of newborn screening. Ment Retard Dev Disabil Res Rev. 2006;12:270\u20139.","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"1055_CR4","unstructured":"EURORDIS. The Voice of Rare Disease Patients in Europe. Key principles for newborn screening. Brussels: EURORDIS. https:\/\/eurordis.org\/newbornscreening 2021."},{"key":"1055_CR5","doi-asserted-by":"publisher","first-page":"S350","DOI":"10.1542\/peds.2005-2633O","volume":"117","author":"D Alexander","year":"2006","unstructured":"Alexander D, van Dyck PC. A vision of the future of newborn screening. Pediatrics 2006;117:S350\u20134.","journal-title":"Pediatrics"},{"key":"1055_CR6","doi-asserted-by":"crossref","unstructured":"Berg JS, Agrawal PB, Bailey DB Jr, Beggs AH, Brenner SE, Brower AM, et al. Newborn sequencing in genomic medicine and public health. Pediatrics. 2017;139:e20162252.","DOI":"10.1542\/peds.2016-2252"},{"key":"1055_CR7","doi-asserted-by":"publisher","first-page":"662254","DOI":"10.3389\/fgene.2021.662254","volume":"12","author":"ZI Remec","year":"2021","unstructured":"Remec ZI, Trebusak Podkrajsek K, Repic Lampret B, Kovac J, Groselj U, Tesovnik T, et al. Next-generation sequencing in newborn screening: a review of current state. Front Genet. 2021;12:662254.","journal-title":"Front Genet."},{"key":"1055_CR8","unstructured":"Health Council of the Netherlands. Screenen op niet-behandelbare aandoeningen vroeg in het leven [Screening for non-treatable disorders early in life]. The Hague: Health Council of the Netherlands https:\/\/www.gezondheidsraad.nl\/documenten\/adviezen\/2020\/09\/30\/screenen-op-niet-behandelbare-aandoeningen-vroeg-in-het-leven 2020."},{"key":"1055_CR9","doi-asserted-by":"crossref","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;5:CD003725.","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"1055_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S1474-4422(18)30115-7","volume":"17","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Mercuri E. Evidence-based care in Duchenne muscular dystrophy. Lancet Neurol. 2018;17:389\u201391.","journal-title":"Lancet Neurol."},{"key":"1055_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12519-019-00242-6","volume":"15","author":"Q Ke","year":"2019","unstructured":"Ke Q, Zhao ZY, Mendell JR, Baker M, Wiley V, Kwon JM, et al. Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy. World J Pediatr. 2019;15:219\u201325.","journal-title":"World J Pediatr."},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jamaneurol.2013.4808","volume":"71","author":"F Tassone","year":"2014","unstructured":"Tassone F. Newborn screening for fragile X syndrome. JAMA Neurol. 2014;71:355\u20139.","journal-title":"JAMA Neurol."},{"key":"1055_CR13","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1542\/peds.2007-0820","volume":"121","author":"DB Bailey Jr","year":"2008","unstructured":"Bailey DB Jr, Skinner D, Davis AM, Whitmarsh I, Powell C. Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues. Pediatrics. 2008;121:e693\u2013704.","journal-title":"Pediatrics."},{"key":"1055_CR14","doi-asserted-by":"publisher","first-page":"F91","DOI":"10.1136\/fn.86.2.F91","volume":"86","author":"EP Parsons","year":"2002","unstructured":"Parsons EP, Clarke AJ, Hood K, Lycett E, Bradley DM. Newborn screening for Duchenne muscular dystrophy: a psychosocial study. Arch Dis Child Fetal Neonatal Ed. 2002;86:F91\u20135.","journal-title":"Arch Dis Child Fetal Neonatal Ed."},{"key":"1055_CR15","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1542\/peds.2009-0269","volume":"125","author":"AM Plass","year":"2010","unstructured":"Plass AM, van El CG, Pieters T, Cornel MC. Neonatal screening for treatable and untreatable disorders: prospective parents\u2019 opinions. Pediatrics. 2010;125:e99\u2013106.","journal-title":"Pediatrics."},{"key":"1055_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/GIM.0b013e3181de695c","volume":"12","author":"CH Wade","year":"2010","unstructured":"Wade CH, Wilfond BS, McBride CM. Effects of genetic risk information on children\u2019s psychosocial wellbeing: a systematic review of the literature. Genet Med. 2010;12:317\u201326.","journal-title":"Genet Med."},{"key":"1055_CR17","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/gim.2015.181","volume":"18","author":"CE Wakefield","year":"2016","unstructured":"Wakefield CE, Hanlon LV, Tucker KM, Patenaude AF, Signorelli C, McLoone JK, et al. The psychological impact of genetic information on children: a systematic review. Genet Med. 2016;18:755\u201362.","journal-title":"Genet Med."},{"key":"1055_CR18","doi-asserted-by":"crossref","unstructured":"Ross LF, Clayton EW. Ethical issues in newborn sequencing research: the case study of BabySeq. Pediatrics. 2019;144:e20191031.","DOI":"10.1542\/peds.2019-1031"},{"key":"1055_CR19","first-page":"17","volume":"3","author":"EP Parsons","year":"2000","unstructured":"Parsons EP, Clarke AJ, Hood K, Bradley DM. Feasibility of a change in service delivery: the case of optional newborn screening for duchenne muscular dystrophy. Community Genet. 2000;3:17\u201323.","journal-title":"Community Genet."},{"key":"1055_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mus.24880","volume":"53","author":"J Chung","year":"2016","unstructured":"Chung J, Smith AL, Hughes SC, Niizawa G, Abdel-Hamid HZ, Naylor EW, et al. Twenty-year follow-up of newborn screening for patients with muscular dystrophy. Muscle Nerve. 2016;53:570\u20138.","journal-title":"Muscle Nerve."},{"key":"1055_CR21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","volume":"21","author":"SJ Moat","year":"2013","unstructured":"Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet. 2013;21:1049\u201353.","journal-title":"Eur J Hum Genet."},{"key":"1055_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijns4010009","volume":"4","author":"T Wotton","year":"2018","unstructured":"Wotton T, Wiley V, Bennetts B, Christie L, Wilcken B, Jenkins G, et al. Are we ready for fragile X newborn screening testing? Lessons learnt from a feasibility study. Int J Neonatal Screen. 2018;4:9.","journal-title":"Int J Neonatal Screen."},{"key":"1055_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2353\/jmoldx.2008.070073","volume":"10","author":"F Tassone","year":"2008","unstructured":"Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008;10:43\u20139.","journal-title":"J Mol Diagn"},{"key":"1055_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","volume":"15","author":"IEC Verhaart","year":"2019","unstructured":"Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15:373\u201386.","journal-title":"Nat Rev Neurol"},{"key":"1055_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1001\/jamaneurol.2015.3537","volume":"73","author":"MA Gatheridge","year":"2016","unstructured":"Gatheridge MA, Kwon JM, Mendell JM, Scheuerbrandt G, Moat SJ, Eyskens F, et al. Identifying non-Duchenne muscular dystrophy-positive and false negative results in prior Duchenne muscular dystrophy newborn screening programs: a review. JAMA Neurol. 2016;73:111\u20136.","journal-title":"JAMA Neurol."},{"key":"1055_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41431-019-0351-3","volume":"27","author":"J Schuurmans","year":"2019","unstructured":"Schuurmans J, Birnie E, van den Heuvel LM, Plantinga M, Lucassen A, van der Kolk DM, et al. Feasibility of couple-based expanded carrier screening offered by general practitioners. Eur J Hum Genet 2019;27:691\u2013700.","journal-title":"Eur J Hum Genet"},{"key":"1055_CR27","unstructured":"VSOP Patient alliance for rare and genetic diseases. Letter to the State Secretary in response to the Health Council\u2019s report \u2018Screening for non-treatable disorders early in life\u2019. Soest: VSOP. https:\/\/vsop.nl\/actueel\/de-vsop-pleit-voor-een-aangepast-besliskader-voor-de-hielprik\/ 2020."},{"key":"1055_CR28","doi-asserted-by":"publisher","unstructured":"Newson AJ. The promise of public health ethics for precision medicine: the case of newborn preventive genomic sequencing. Hum Genet. 2021, https:\/\/doi.org\/10.1007\/s00439-021-02269-0. Online ahead of print.","DOI":"10.1007\/s00439-021-02269-0"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01055-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01055-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T14:03:15Z","timestamp":1665496995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01055-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1038\/s41431-022-01055-4","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"8 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors are staff and member of the Committee of the Health Council of the Netherlands that has drawn up the report discussed in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}